Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report

Immune checkpoint inhibitor (ICI)‐related massive hemoptysis with cavitation has rarely been identified. Here, we report a case of advanced lung adenocarcinoma with lethal bleeding after eight cycles of pembrolizumab. A 55‐year‐old male was diagnosed with stage IV non‐small cell lung cancer (NSCLC). Following confirmation of high programmed death‐ligand 1 (PD‐L1) expression of 60% cancer cells, he subsequently received pembrolizumab monotherapy. His symptoms and chest images significantly improved after four cycles of therapy. However, after eight cycles of immunotherapy, he presented with recurrence of bloody sputum and shortness of breath. Pembrolizumab was discontinued and a diagnosis of checkpoint inhibitor‐associated pneumonitis (CIP) was made. When the CIP was absorbed after glucocorticoid therapy, the patient died of sudden massive hemoptysis with cavitation in the lesion. Key points Although checkpoint inhibitor associated pneumonitis was the leading cause of ICI‐related death, clinicians should be alerted to the finding that more attention should be given to hemoptysis attributed to ICI therapy in advanced lung cancer.